Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.03
-0.04 (-0.89%)
At close: Aug 1, 2025, 4:00 PM
5.13
+0.10 (2.09%)
After-hours: Aug 1, 2025, 4:15 PM EDT
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $3.03M in the quarter ending March 31, 2025, a decrease of -94.62%. This brings the company's revenue in the last twelve months to $20.86M, down -73.79% year-over-year. In the year 2024, Vir Biotechnology had annual revenue of $74.21M, down -13.90%.
Revenue (ttm)
$20.86M
Revenue Growth
-73.79%
P/S Ratio
32.98
Revenue / Employee
$51,130
Employees
408
Market Cap
695.34M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VIR News
- 3 days ago - Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
- 10 days ago - Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors - Business Wire
- 10 days ago - Vir Biotechnology: Hep B And Cancer Projects March On - Seeking Alpha
- 11 days ago - Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
- 7 weeks ago - 20 stocks you should avoid — no matter how well the market does - Market Watch
- 2 months ago - Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - Business Wire
- 2 months ago - Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - Business Wire
- 2 months ago - Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - Business Wire